New antiplatelet agents: Why they are needed

Massimo Franchini, Pier Mannuccio Mannucci

Research output: Contribution to journalArticlepeer-review


Despite recent advances in the treatment of acute coronary syndromes (ACS), including dual antiplatelet therapy with aspirin and a thienopyridine during the acute phase and for secondary prevention, this condition remains a leading cause of morbidity and mortality. The limitations of the currently available antiplatelet agents have triggered the development of newer drugs. In this review we summarize the mechanisms of actions and results of current clinical trials of novel antiplatelet agents. These include prasugrel, a thienopyridine prodrug which has a mechanism similar to that of clopidogrel but superior pharmacokinetic features; ticagrelor, a non-thienopyridine that binds reversibly to the platelet P2Y 12 receptor; cangrelor, an intravenously administered analog of ticagrelor; the thrombin receptor antagonist SCH 53048; and terutroban (S18886), a thromboxane A 2 receptor inhibitor.

Original languageEnglish
Pages (from-to)733-738
Number of pages6
JournalEuropean Journal of Internal Medicine
Issue number8
Publication statusPublished - Dec 2009


  • Antiplatelet agents
  • Cangrelor
  • Prasugrel
  • SCH 530348
  • Terutroban
  • Ticagrelor

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'New antiplatelet agents: Why they are needed'. Together they form a unique fingerprint.

Cite this